
Please try another search
Rize Oncology Inc., a biopharmaceutical company, focuses on the development of precision gene editing for human therapeutics applications. It develops STS-201, a small-molecule drug for the treatment of soft tissue sarcoma. The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc. in January 2025. Rize Oncology Inc. was incorporated in 2018 and is based in Kelowna, Canada.
Name | Age | Since | Title |
---|---|---|---|
P. Gage Jull | 65 | 2021 | Independent Director |
William James Garner | 59 | 2018 | Co-Founder & Executive Director |
Andre Pereira Fraga Figueiredo | 48 | 2021 | Independent Director |
Daren N. Graham | 53 | 2021 | Interim CEO & Executive Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review